# Creandum and USV Lead $40M Seed Round for Machenta A robotics startup secures significant early-stage funding despite having no commercial product yet. - **Source:** [Sifted](https://sifted.eu) - **Published:** 2026-10-30 - **Topic:** [Finance](https://brifing.si/c/finance) - **Original article:** - **On Brifing:** https://brifing.si/s/e5bc6fd0-d0a7-4943-84a4-202e9bf340cd ## Unprecedented Seed Capital Injection Machenta has successfully secured a substantial 40 million dollar seed investment round. This significant capital infusion was co-led by prominent venture capital firms Creandum and Union Square Ventures. Despite the absence of a finalized commercial product, investors have demonstrated immense confidence in the company's underlying robotics research and development capabilities. ## Strategic Investor Confidence The decision by Creandum and USV to lead this round highlights a specific appetite for deep-tech ventures. These firms are betting on the long-term potential of Machenta's laboratory-stage innovations rather than immediate market readiness. This investment structure reflects a growing trend where institutional capital supports foundational robotics research before commercialization. ## The Robotics Lab Model Machenta operates primarily as a robotics laboratory rather than a traditional product-focused startup. This operational model prioritizes iterative engineering and fundamental research over rapid prototyping for consumer markets. By functioning as a lab, the company focuses on solving complex technical challenges that currently prevent widespread automation in various industrial sectors. ## Absence of Commercial Product The startup currently lacks a tangible product available for sale or deployment. This situation is unconventional for a seed-stage company, which typically demonstrates a minimum viable product to secure funding. However, the investors are prioritizing the team's technical expertise and intellectual property portfolio over current revenue-generating capabilities or market-ready hardware. ## Capital Allocation Strategy The 40 million dollars will likely be utilized to scale the laboratory infrastructure and expand the engineering team. Significant resources are required to maintain high-end robotics hardware and software development environments. The capital provides a long runway for the company to transition from theoretical research to functional prototypes without immediate pressure. ## Market Context for Robotics The robotics sector is currently experiencing a shift toward high-risk, high-reward investments in foundational technology. Investors are increasingly willing to fund companies that tackle systemic automation issues rather than incremental improvements. This capital injection underscores the belief that the next generation of robotics will emerge from deep-tech research labs. ## Investor Risk Assessment Backing a company without a product involves substantial technical and execution risks for the lead investors. Creandum and USV are effectively underwriting the research phase of Machenta's development lifecycle. This strategy suggests that the due diligence process focused heavily on the technical feasibility and the potential scalability of the core robotics architecture. ## Future Development Trajectory The success of this funding round sets a high benchmark for future robotics startups seeking early-stage capital. Machenta must now demonstrate tangible progress in its research milestones to justify the valuation. The industry will closely monitor how this laboratory-first approach translates into functional robotics solutions that eventually reach commercial viability. ## Sources covering this story - https://sifted.eu/articles/creandum-usv-40m-seed-uk-robotics-lab-no-product/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._